Contrary to the belief that any interstitial lung disease (ILD) requires permanent discontinuation of TDXD, data shows patients with asymptomatic, radiographically-identified Grade 1 ILD can be safely rechallenged. Treatment is paused and the patient is treated, but therapy can resume once resolved. Symptomatic ILD, however, requires permanent discontinuation.

The discovery of low-grade, asymptomatic interstitial lung disease (ILD) on scans for patients on certain ADCs does not mandate permanent discontinuation. By holding the drug, initiating steroids, and involving pulmonology, the inflammation can resolve, often allowing the patient to safely resume a highly effective therapy.

To manage the risk of interstitial lung disease (ILD) with TDXD, experts now recommend routine screening with high-resolution chest CT scans every 6-12 weeks. This practice aims to catch asymptomatic, grade 1 ILD early, allowing for treatment holds and steroid intervention, which may preserve the option to rechallenge.

The goal of advanced in-home health tech is not just to track vitals but to use AI to analyze subtle changes, like gait. By comparing data to population norms and personal baselines, these systems can predict issues and enable early, less invasive interventions before a crisis occurs.

Unlike some immunotherapy guidelines, experts recommend immediate steroid treatment for even Grade 1 (asymptomatic) ADC-induced pneumonitis or interstitial lung disease (ILD) found on scans. This aggressive, proactive approach is considered necessary due to the risk of rapid clinical deterioration, prioritizing safety and the ability to resume cancer therapy.

The "Hospital at Home" model is evolving beyond just discharging patients early. Healthcare systems can now admit patients directly to their own homes for acute conditions like pneumonia or skin infections, bypassing the traditional hospital stay entirely. This represents a fundamental shift in how acute care is delivered, moving from a centralized facility to a distributed, home-based model.

Healthcare systems were designed for acute, symptomatic diseases. This "wait for the patient" model is ineffective for chronic conditions like hypertension, which are often asymptomatic for years. The future requires a shift from sporadic visits to continuous, proactive, tech-enabled care.

Recovering at home is not just more pleasant; it's often clinically safer and more effective. Patients are less likely to contract dangerous hospital-acquired infections (nosocomial infections), tend to mobilize more, and experience better overall outcomes. This reframes the "Hospital at Home" model as a medically superior option for certain patients, not just a cheaper or more convenient one.

Contrary to initial fears, both clinical trial and real-world data show that patients experiencing asymptomatic, grade 1 interstitial lung disease (ILD) from TDXD can be safely retreated. This allows patients to continue benefiting from a highly effective therapy without undue risk.